ArticleFrontiers in bioengineering and biotechnology2018
Capacities for the Risk Assessment of GMOs: Challenges to Build Sustainable Systems.
Article in Frontiers in bioengineering and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genetically modified microorganisms for agricultural use: an opportunity for the advancement of risk assessment criteria in Argentina.Frontiers in bioengineering and biotechnology · 2025Article
- Regulatory landscape for new breeding techniques (NBTs): insights from Paraguay.Frontiers in bioengineering and biotechnology · 2024Article
- Graduate certificate on risk analysis for the Agrifood sector at the University of Buenos Aires.Frontiers in bioengineering and biotechnology · 2024Article
- Paraguay's approach to biotechnology governance: a comprehensive guide.Frontiers in bioengineering and biotechnology · 2024Article
- Perception of genetically engineered crops in Paraguay.GM crops & food · 2021Article
- Paraguay's Path Toward the Simplification of Procedures in the Approval of GE Crops.Frontiers in bioengineering and biotechnology · 2020Article
- Roads Forward for European GMO Policy-Uncertainties in Wake of ECJ Judgment Have to be Mitigated by Regulatory Reform.Frontiers in bioengineering and biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need for functional risk assessment bodies in general, and in the biosafety field in particular, demands continued efforts and commitment from regulatory agencies, if results that are sustainable in time are to be achieved. The lack of formal processes that ensure continuity in the application of state of the art scientific criteria, the high rotation in some cases or the lack of experienced professionals, in others, is a challenge to be addressed. Capacity building initiatives with different approaches and degrees of success have been implemented in many countries over the years, supported by diverse governmental and non-governmental organizations. This document summarizes some capacity building experiences in developing countries and concludes that risk assessors taking ownership and regulatory authorities fully committed to developing and retaining highly qualified bodies are a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.